ArticleBMC microbiology2014
Saccharomyces cerevisiae biofilm tolerance towards systemic antifungals depends on growth phase.
Article in BMC microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Central Line-Related Bloodstream Infection byMicroorganisms · 2025Article
- An Optimized LIVE/DEAD Assay Coupled with Flow Cytometry for Quantifying Post-Stress Survival in Yeast Cells.Journal of visualized experiments : JoVE · 2025Article
- An Optimized LIVE/DEAD Assay Using Flow Cytometry to Quantify Post-Stress and Antifungal-Treatment Survival in Diverse Yeasts.bioRxiv : the preprint server for biology · 2025Article
- Gut and bladder fermentation syndromes: a narrative review.BMC medicine · 2024Review
- A case of bloodstream co-infection of Saccharomyces cerevisiae and Candida glabrata while using micafungin.BMC infectious diseases · 2023Article
- Metabolic heterogeneity and cross-feeding within isogenic yeast populations captured by DILAC.Nature microbiology · 2023Article
- SARS-CoV-2 Post-Infection and Sepsis byTropical medicine and infectious disease · 2023Article
- Identifying genetic variants associated with amphotericin B (AMB) resistance inFrontiers in genetics · 2023Article
- On the Ecological Significance of Phenotypic Heterogeneity in Microbial Populations Undergoing Starvation.Microbiology spectrum · 2022Article
- What 'Omics can tell us about antifungal adaptation.FEMS yeast research · 2022Review
- Antimicrobial Activity and Toxicity of Analogs of Wasp Venom EMP Peptides. Potential Influence of Oxidized Methionine.Antibiotics (Basel, Switzerland) · 2021Article
- Visible Lights Combined with Photosensitizing Compounds Are Effective against Candida albicans Biofilms.Microorganisms · 2021Article
- Photodynamic Therapy Is Effective AgainstFrontiers in cellular and infection microbiology · 2021Article
- Cellular quiescence in budding yeast.Yeast (Chichester, England) · 2021Review
- Article
- Fungal biofilm architecture produces hypoxic microenvironments that drive antifungal resistance.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Aspects of Multicellularity inGenes · 2020Review
- Abrogation of pathogenic attributes in drug resistant Candida auris strains by farnesol.PloS one · 2020Article
- New diphenylphosphane derivatives of ketoconazole are promising antifungal agents.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiofilm-forming Candida species cause infections that can be difficult to eradicate, possibly because of antifungal drug tolerance mechanisms specific to biofilms. In spite of decades of research, the connection between biofilm and drug tolerance is not fully understood.
resultsWe used Saccharomyces cerevisiae as a model for drug susceptibility of yeast biofilms. Confocal laser scanning microscopy showed that S. cerevisiae and C. glabrata form similarly structured biofilms and that the viable cell numbers were significantly reduced by treatment of mature biofilms with amphotericin B but not voriconazole, flucytosine, or caspofungin. We showed that metabolic activity in yeast biofilm cells decreased with time, as visualized by FUN-1 staining, and mature, 48-hour biofilms contained cells with slow metabolism and limited growth. Time-kill studies showed that in exponentially growing planktonic cells, voriconazole had limited antifungal activity, flucytosine was fungistatic, caspofungin and amphotericin B were fungicidal. In growth-arrested cells, only amphotericin B had antifungal activity. Confocal microscopy and colony count viability assays revealed that the response of growing biofilms to antifungal drugs was similar to the response of exponentially growing planktonic cells. The response in mature biofilm was similar to that of non-growing planktonic cells. These results confirmed the importance of growth phase on drug efficacy.
conclusionsWe showed that in vitro susceptibility to antifungal drugs was independent of biofilm or planktonic growth mode. Instead, drug tolerance was a consequence of growth arrest achievable by both planktonic and biofilm populations. Our results suggest that efficient strategies for treatment of yeast biofilm might be developed by targeting of non-dividing cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.